Stevens Capital Management’s Takeda Pharmaceutical TAK Stock Holding History

Stevens Capital Management’s Portfolio TAK Stock Details TAK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-14,030	Closed	-$255K	–	218
2020 Q4	$255K	Buy	+14,030	New	+$246K	0.13%	126
2020 Q1	–	Sell	-22,190	Closed	-$438K	–	399
2019 Q4	$438K	Buy	22,190 +7,928	+56%	+$152K	0.04%	375
2019 Q3	$245K	Buy	+14,262	New	+$247K	0.02%	486
2019 Q2	–	Sell	-38,439	Closed	-$783K	–	840
2019 Q1	$783K	Buy	+38,439	New	+$774K	0.03%	438

Other funds holding TAK

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

GCM

Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

PPA

Parametric Portfolio Associates Seattle, Washington $190B AUM 18.52% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

MIP

Mondrian Investment Partners London, United Kingdom $6.69B AUM

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Stevens Capital Management's TAK Position: Q1 2021 in Review

Stevens Capital Management sold out of Takeda Pharmaceutical (TAK) in Q1 2021, closing a stake of 14,030 shares — an estimated $255K sold.

Stevens Capital Management first reported a position in TAK in Q1 2019 and held it in 4 quarters. The position peaked at $783K in Q1 2019. 316 funds tracked by Wall St. Rank hold TAK as of Q1 2021.

Stevens Capital Management reported no remaining Takeda Pharmaceutical position as of Q1 2021 after selling out during the quarter.
Stevens Capital Management sold 14,030 Takeda Pharmaceutical shares in Q1 2021, an estimated $255K.
Stevens Capital Management first reported a position in Takeda Pharmaceutical in Q1 2019 and held it in 4 quarters.
Stevens Capital Management's Takeda Pharmaceutical position peaked at $783K in Q1 2019.
316 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q1 2021.

Based on Stevens Capital Management's 13F filing for Q1 2021, filed 11 May 2021.